GREENWICH LIFESCIENCES, INC.


Associated tags: Phase, MD Anderson Cancer Center, Immunotherapy, Patient, Cancer, Breast, Breast cancer, Health, Biotechnology, Pharmaceutical, Pharmaceutical industry, Woman, Recurrence, DTH, Trastuzumab, Clinical Trials, HER2/neu, Survivor, HLA, Oncology

Locations: US, EUROPE, TEXAS, UNITED STATES, NORTH AMERICA, STAFFORD, TX, GREENWICH

Greenwich LifeSciences to Participate in Multiple Virtual Investor Conferences During 2021 JP Morgan Healthcare Week

Retrieved on: 
Friday, January 8, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Cancer immunotherapy, Immunotherapy, Virotherapy, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal Patel, CEO of Greenwich LifeSciences, will participate in three virtual investor conferences during the week of January 11, 2021.

Key Points: 
  • Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Snehal Patel, CEO of Greenwich LifeSciences, will participate in three virtual investor conferences during the week of January 11, 2021.
  • The Company will be participating in the BIO partnering event at the 2021 JP Morgan Healthcare Conference.
  • Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.

Greenwich LifeSciences’ LD Micro Presentation Replay Now Available

Retrieved on: 
Tuesday, January 5, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health sciences, Health, Clinical research, Pharmaceutical industry, Microcap stock, Stock market, Clinical trial, Medical research, LD Micro, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc.

To view the replay from the LD Micro main page, please navigate to the Tuesday schedule under Track 2.

Key Points: 
  • To view the replay from the LD Micro main page, please navigate to the Tuesday schedule under Track 2.
  • LD Micro is the host of the most influential conferences in the small-cap world.
  • LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.

Greenwich LifeSciences to Ring Nasdaq Opening Bell on December 28

Retrieved on: 
Thursday, December 24, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that it will ring the Nasdaq opening bell on December 28, 2020, in celebration of its recently completed initial public offering (IPO).

Key Points: 
  • Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that it will ring the Nasdaq opening bell on December 28, 2020, in celebration of its recently completed initial public offering (IPO).
  • Snehal Patel, CEO of Greenwich LifeSciences, will be joined by members of the Greenwich LifeSciences team for the virtual ceremony, which will begin at approximately 9:20 am EST.
  • I am honored to virtually ring the Nasdaq opening bell on behalf of the Greenwich LifeSciences team, commented Patel.
  • The bell ringing ceremony is a great opportunity to celebrate the major milestone of the Company going public.

Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Common Stock

Retrieved on: 
Tuesday, December 22, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Initial public offering, Financial economics, Finance, Financial markets, Prospectus, Registration statement, Form S-1, Public offering, Clinical trial, Red herring prospectus

The Company has also granted the underwriters a 45-day option to purchase up to an additional 99,000 shares of common stock offered in the public offering to cover over-allotments, if any, at the public offering price, which would increase the total gross proceeds of the offering to approximately $30.4 million, if exercised in full.

Key Points: 
  • The Company has also granted the underwriters a 45-day option to purchase up to an additional 99,000 shares of common stock offered in the public offering to cover over-allotments, if any, at the public offering price, which would increase the total gross proceeds of the offering to approximately $30.4 million, if exercised in full.
  • This offering was made pursuant to a registration statement on Form S-1 (File No.
  • A final prospectus related to the offering was filed and is available on the SEC's website.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.

Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock

Retrieved on: 
Friday, December 18, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical trials, Financial markets, Financial economics, Finance, Stock market, Corporate finance, Initial public offering, Equity securities, Stock, Security, Public offering, Greenshoe, Follow-on offering

The public offering equates to 660,000 shares of the Companys common stock at a price of $40.00 per share.

Key Points: 
  • The public offering equates to 660,000 shares of the Companys common stock at a price of $40.00 per share.
  • The Company has also granted the underwriters a 45-day option to purchase up to an additional 99,000 shares of common stock offered in the public offering to cover over-allotments, if any, at the public offering price, which would increase the total gross proceeds of the offering to approximately $30.4 million, if exercised in full.
  • The offering is expected to close on or about December 22, 2020, subject to customary closing conditions.
  • A registration statement relating to the shares of common stock being sold in this offering was declared effective by the Securities and Exchange Commission (the SEC) on December 17, 2020.

Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates

Retrieved on: 
Tuesday, December 15, 2020
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical research, Medicine, Health sciences, Vaccines, Vaccination, COVID-19 vaccine, Vaccine, Hypothetical technology, HIV vaccine, Vaxart, Westport Bio, Greenwich LifeSciences, Inc.

Westport Bios coronavirus vaccine program includes up to 7 vaccine candidates which are designed to complement or improve upon the DNA/RNA based coronavirus vaccines that are in advanced Phase III clinical trials or that have recently been approved by the FDA for emergency use.

Key Points: 
  • Westport Bios coronavirus vaccine program includes up to 7 vaccine candidates which are designed to complement or improve upon the DNA/RNA based coronavirus vaccines that are in advanced Phase III clinical trials or that have recently been approved by the FDA for emergency use.
  • The collaboration has been expanded to include a coronavirus vaccine program using similar technology.
  • The coronavirus vaccine technology makes use of multiple antigens that would complement strategies that rely solely on the spike protein as the principal antigen.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.

Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer

Retrieved on: 
Friday, December 11, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Health, Cancer treatments, Immunology, Trastuzumab, HER2/neu, Breast cancer, Trastuzumab emtansine, NeuVax, SABCS, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the publication of a second poster for the GP2 Phase III clinical trial design for recurring breast cancer at the San Antonio Breast Cancer Symposium (SABCS) in a virtual format.

Key Points: 
  • Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the publication of a second poster for the GP2 Phase III clinical trial design for recurring breast cancer at the San Antonio Breast Cancer Symposium (SABCS) in a virtual format.
  • View the full release here: https://www.businesswire.com/news/home/20201211005203/en/
    Poster OT-13-03: GP2 Phase III Clinical Trial Design for Recurring Breast Cancer (Graphic: Business Wire)
    Poster OT-13-03 is entitled: A prospective, randomized, multicenter, double-blinded, placebo-controlled Phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.
  • Snehal Patel, CEO of Greenwich LifeSciences, commented, We are preparing diligently for our pivotal Phase III clinical trial, aligning ourselves with one of the leading cancer institutions in the world.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.

Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer

Retrieved on: 
Wednesday, December 9, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Clinical medicine, Medical specialties, Health, Antibody-drug conjugates, Immunology, Breast cancer, Trastuzumab emtansine, Metastatic breast cancer, Trastuzumab, SABCS, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc.

Approximately 50% of women with recurring breast cancer do not respond to Herceptin or Kadcyla, resulting in metastatic breast cancer and a poor prognosis.

Key Points: 
  • Approximately 50% of women with recurring breast cancer do not respond to Herceptin or Kadcyla, resulting in metastatic breast cancer and a poor prognosis.
  • The 43rd annual SABCS has grown to be the industrys premier breast cancer conference for basic, translational, and clinical cancer research professionals.
  • Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.

Greenwich LifeSciences Announces New Manufacturing Agreement for its Planned Phase III Clinical Trial and Enters into Lease for Office and Lab Space

Retrieved on: 
Thursday, December 3, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health sciences, Health, Pharmaceutical industry, Life sciences, Clinical research, Design of experiments, Clinical pharmacology, Clinical trial, Good manufacturing practice, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc.

In addition, the Company has leased office, laboratory, and storage space to provide research, manufacturing, and clinical trial support activities.

Key Points: 
  • In addition, the Company has leased office, laboratory, and storage space to provide research, manufacturing, and clinical trial support activities.
  • The Companys new manufacturing partner specializes in the current Good Manufacturing Practice (cGMP) of formulating, filling, and labeling drug vials and follows the recent completion of the manufacturing of the GP2 active ingredient.
  • The Companys new facility is located in Stafford, Texas and will enable the Company to support its manufacturing activities, develop analytical methods, and process clinical trial samples.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.

Greenwich LifeSciences to Present at the Annual LD Micro Main Event

Retrieved on: 
Wednesday, December 2, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Stock market, Microcap stock, LD Micro, Breast Cancer and HER2/neu Positivity, Greenwich LifeSciences, Inc.

Snehal Patel, CEO of Greenwich LifeSciences, will present and then participate in a live Q&A session by a panel of investors.

Key Points: 
  • Snehal Patel, CEO of Greenwich LifeSciences, will present and then participate in a live Q&A session by a panel of investors.
  • LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.
  • What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).
  • For more information on Greenwich LifeSciences, please visit the companys website: www.greenwichlifesciences.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005372/en/